{
  "Advanced phase CML": {
    "Treatment considerations": [
      "Disease progression to advanced phase while on TKI therapy has worse prognosis than de novo advanced phase CML",
      "Evaluation for allogeneic HCT as indicated",
      "Selection of TKI is based on prior therapy and/or BCR::ABL1 mutation profile",
      "CNS involvement has been described in BP-CML. Lumbar puncture and CNS prophylaxis is recommended for lymphoid BP-CML"
    ],
    "Subtype": {
      "AP-CML": {
        "Treatment": {
          "Options": [
            "Clinical trial",
            "Preferred regimens: 2G TKI (Bosutinib, Dasatinib, or Nilotinib) or 3G TKI (Ponatinib)"
          ],
          "Useful in certain circumstances": [
            "1G TKI (Imatinib) if 2G or 3G TKI is contraindicated",
            "Allosteric TKI (Asciminib)"
          ],
          "If lack of response or disease progression": "Allogeneic HCT (CML-6)"
        }
      },
      "BP-CML": {
        "Lineage": {
          "Lymphoid": {
            "Treatment": {
              "Options": [
                "Clinical trial",
                "Preferred regimens: ALL-type induction chemotherapy (NCCN Guidelines for ALL) + TKI"
              ],
              "Useful in certain circumstances": [
                "TKI + steroids (if not a candidate for induction chemotherapy)"
              ],
              "For patients in remission": [
                "Allogeneic HCT (CML-6)",
                "Consolidation chemotherapy and TKI maintenance for non-candidates for allogeneic HCT"
              ]
            }
          },
          "Myeloid": {
            "Treatment": {
              "Options": [
                "Clinical trial",
                "Preferred regimens: AML-type induction chemotherapy (NCCN Guidelines for AML) + TKI"
              ],
              "Useful in certain circumstances": [
                "TKI (if not a candidate for induction chemotherapy)"
              ],
              "For patients in remission": [
                "Allogeneic HCT (CML-6)",
                "Consolidation chemotherapy and TKI maintenance for non-candidates for allogeneic HCT"
              ]
            }
          }
        }
      }
    }
  }
}